Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity
Abstract Non-small cell lung cancer (NSCLC) ranks as one of the leading causes of cancer-related deaths worldwide. Despite the prominence and effectiveness of kinase-target therapies in NSCLC treatment, these drugs are suitable for and beneficial to a mere ~30% of NSCLC patients. Consequently, the n...
Main Authors: | Tao Yuan, Chenming Zeng, Jiawei Liu, Chenxi Zhao, Fujing Ge, Yuekang Li, Meijia Qian, Jiamin Du, Weihua Wang, Yonghao Li, Yue Liu, Xiaoyang Dai, Jianya Zhou, Xueqin Chen, Shenglin Ma, Hong Zhu, Qiaojun He, Bo Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2024-01-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-023-01706-y |
Similar Items
-
LKB1 Positively Regulates Dendritic Cell-induced T Cell Immunity and Suppresses Tumor Development
by: Wenjie Zhang, et al.
Published: (2023-06-01) -
LKB1 suppression promotes cardiomyocyte regeneration via LKB1-AMPK-YAP axis
by: Shuang Qu, et al.
Published: (2022-09-01) -
A Joséphine Bacon
by: Aurélia Lassaque
Published: (2022-11-01) -
Josephine Savathrinathan become lawyer
by: Makkal, Osai
Published: (2016) -
At the Margins: The Art of Josephine Tota
by: Jessica Marten
Published: (2016-10-01)